Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

US phase III trial of nabiximols (Sativex) for spasticity due to multiple sclerosis

Trial Profile

US phase III trial of nabiximols (Sativex) for spasticity due to multiple sclerosis

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Muscle spasticity
  • Focus Registrational; Therapeutic Use
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 05 Nov 2019 According to the GW Pharmaceuticals media release, the company expected to commence this study in Q1 2020.
    • 26 Feb 2019 According to the GW Pharmaceuticals media release, this trial is expected to begin in Q4 2019.
    • 07 May 2014 According to the GW Pharmaceuticals media release published on 7 May 2014, the US FDA granted Special Protocol Assessment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top